1 / 22

PET E TUMORI NEUROENDOCRINI: NUOVI TRACCIANTI Stefano Fanti

PET E TUMORI NEUROENDOCRINI: NUOVI TRACCIANTI Stefano Fanti. 18 F-DOPA PET. Somatostatin Receptor PET. 18 F-DOPA PET. CLINICAL APPLICATIONS. NEUROLOGY: Movement disorders (Parkinson Disease). ONCOLOGY: Neuroendocrine tumors Pheochromocytoma Neuroblastoma (?). F-DOPA. FDG.

leia
Télécharger la présentation

PET E TUMORI NEUROENDOCRINI: NUOVI TRACCIANTI Stefano Fanti

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PET E TUMORI NEUROENDOCRINI: NUOVI TRACCIANTI Stefano Fanti

  2. 18F-DOPA PET Somatostatin Receptor PET

  3. 18F-DOPA PET

  4. CLINICAL APPLICATIONS NEUROLOGY: Movement disorders (Parkinson Disease) ONCOLOGY: Neuroendocrine tumors Pheochromocytoma Neuroblastoma (?)

  5. F-DOPA FDG M, 59yo. Metastatic carcinoid.

  6. F 45yo: staging of metastatic carcinoid. Several bone lesions

  7. Male,62yo. Secondary lesions within the liver. Unknown primary.

  8. Male,58yo. Ileum NET already operated (2004). Restaging

  9. Female,30yo. Diffuse secondary lesions within the liver. Unknown primary.

  10. Male,52yo. Secondary lesions within the liver. Unknown primary.

  11. Somatostatin Receptor PET

  12. Somatostatin Receptor PET

  13. Somatostatin Receptor PET

  14. Somatostatin Receptor PET

  15. Somatostatin Receptor PET

  16. 68Gallium

  17. DOTA-WHAT ?

  18. Somatostatin Receptor PET

More Related